Composition for controlling proliferation of bacteria in intestinal tract and use thereof
By using human milk oligosaccharides and their derivatives to control the proliferation of Egertella, Fertilizer, Holdman's Halderella and Parasatella in the intestine, disorders such as intestinal bacterial proliferation and depression have been solved. Related issues have achieved effective regulation of these bacterial proliferation and improvement of related diseases.
Patent Information
- Application Number
- CN202380027908.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-18
- Filing Date
- 2023-03-17
- Publication Date
- 2024-11-01
AI Technical Summary
The prior art is difficult to effectively control the proliferation of Egertella, Fertilizer, Holdmannia and Parasatis in the intestine, and these bacteria are related to mood disorders such as depression, and lack effective inhibitory methods.
Human milk oligosaccharides and their derivatives, such as fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, etc., are used as active ingredients of the composition to control the proliferation of these bacteria through specific sugar structures. , including inhibition and promotion.
Effectively control the proliferation share of these bacteria in the intestines, and is used to treat or prevent related diseases such as inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, mood disorders and asthma, and improve depression and other mental and behavioral disorders.
Smart Images

Figure CN118890973A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a composition for controlling the proliferation of bacteria in the intestinal tract and its use. Background Art
[0002] In recent years, it has been established that gut bacteria have an impact on various physiological functions of the host, and it has also been shown that gut bacteria are associated with mental and behavioral disorders, including mood disorders such as depression.
[0003] It is reported that the results of giving feces of depression patients and healthy people to germ-free mice showed that the depressive-like behavior of mice given feces of depression patients increased compared with mice given feces of healthy people (Non-patent Document 1). In addition, in a systematic review comparing intestinal bacteria of healthy people and people with depression, it was reported that in patients with depression, there were more intestinal bacteria of 24 genera, including bacteria of the genus Eggerthella, bacteria of the genus Oscillibacter, bacteria of the genus Holdemania, and bacteria of the genus Parasutterella (Non-patent Document 2).
[0004] About Eggerthella bacteria, as the means to reduce it, known antibiotics such as metronidazole and vancomycin (non-patent literature 3). In addition, it is reported that when giving 4 weeks of plant lactobacillus (Lactobaccilusplantarum) CCFM1143 to chronic diarrhea patients, clinical symptoms were relieved, in addition, intestinal flora was regulated, especially the amount of Bacteroides (Bacteroides) and Eggerthella (Eggerthella) (non-patent literature 4) was reduced. Further, in patent documentation 1, a kind of oligosaccharide also included in vegetables, cereals such as onion, garlic, barley, rye, i.e., 1-kestose is an antibacterial agent of Eggerthella bacteria of effective ingredient is recorded, and the preparation is recorded for preventing or treating diseases, and the disease is selected from bacteremia, sinusitis, pyomyositis, skin abscess, discitis and liver abscess caused by type 2 diabetes and Eggerthella bacteria.
[0005] Regarding Oscillator bacteria, it is reported that pretreatment of rats with acute heart failure with Bifidobacterium longum R0175 can reduce the relative amount of potentially harmful bacteria such as Oscillator bacteria, and partially restore the intestinal flora abnormalities of rats with liver damage (non-patent document 5). In addition, it is reported that isoorientin inhibits the proliferation of Oscillator bacteria that may cause inflammation of the intestinal flora of mice (non-patent document 6). Further, it is reported that when mice are given nicotinamide mononucleotide (NMN), butyrate-producing bacteria increase in their feces, and several harmful bacteria including Oscillator bacteria decrease (non-patent document 7). In addition, Patent Document 2 records that crude drugs, natural products, herbs, or compositions containing herbs selectively increase the first intestinal flora in the subject, while reducing the second intestinal flora. The document also records that the first intestinal flora contains bacteria that produce short-chain fatty acids (SCFA), and one of the first intestinal flora is Oscillator. In addition, Patent Document 3 describes a composition for fecal microbiota transplantation, which is used to prevent or alleviate inflammation induced by systemic and intestinal treatments, and describes Oscillator as one of the bacteria that increase after fecal transplantation. Furthermore, Patent Document 4 describes that soluble corn fiber increases Oscillator and the like.
[0006] Regarding bacteria of the genus Holdemania, it is reported that a decrease in bacteria such as Holdemania filiformis was observed at the species level in the intestinal flora of healthy people who orally ingested a probiotic product containing Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 for one month (Non-Patent Document 8). In addition, in the above-mentioned Patent Document 2, Holdemania is described as one of the bacteria contained in the first intestinal flora.
[0007] Regarding Parasutterella bacteria, it is reported that they have a high incidence in patients with major depression and depression (Non-Patent Documents 9, 10). In addition, in an experiment aimed at evaluating the effects of inulin and metformin on the inhibition of polycystic ovary syndrome (PCOS) in mice and their related mechanisms, it was reported that inulin and metformin improved the morphology of PCOS, and the results of sequence analysis of intestinal flora showed that Bifidobacterium increased in the inulin intake group, while Proteobacteria, Helicobacter pylori, and Parasutterella decreased (Non-Patent Document 11).
[0008] On the other hand, human milk oligosaccharides (HMO) are the third most abundant component in breast milk solids after lactose and lipids. It is known that administration of 2'-fucosyllactose, 3-fucosyllactose, and lacto-bifucotetraose, which are one type of human milk oligosaccharides, increases the proliferation of bifidobacteria (Non-Patent Document 12).
[0009] Prior art literature
[0010] Patent Literature
[0011] Patent Document 1: Japanese Patent Application Publication No. 2020-143020
[0012] Patent Document 2: WO2013 / 182038 (Japanese Patent Publication No. 2015-520176)
[0013] Patent Document 3: WO2020 / 016445 (Japanese Patent Publication No. 2021-530527)
[0014] Patent Document 4: Japanese Patent Application Publication No. 2020-120675
[0015] Non-patent literature
[0016] Non-patent literature 1: Gut microbiome remodeling induces depressive-likebehaviors through a pathway mediated by the host's metabolism. MolPsychiatry.2016;21(6):786-796.doi:10.1038 / mp.2016.44
[0017] Non-patent literature 2: Altered Composition of Gut Microbiota in Depression: A Systematic Review. Front Psychiatry. 2020; 11: 541. Published 2020Jun 10. doi: 10.3389 / fpsyt.2020.00541
[0018] 3:Bo J,Wang S,Bi Y,Ma S,Wang M,Du Z.Eggerthella slowbloodstreaminfections: two cases and review of the literature[publishedcorrection appears in Future Microbiol.2020Nov:15:1689].FutureMicrobiol.2020:15:981–985.doi:10.2217 / fmb-2019-0338
[0019] Materials 4:Yang B,Yue Y,Chen Y,et al.Lactobacillus plantarumCCFM1143 Alleviates Chronic Diarrhea via Inflammation Regulation and GutMicrobiota Modulation:A Double-Blind,Randomized,Placebo-ControlledStudy.Front Immunol.2021|12:746585.Doi:10.3389 / fimmu.2021.746585
[0020] Materials 5:Wang K, Lv L, Yan R, et al.Bifidobacterium longumR0175 Protects Rats against d-Galactosamine-Induced Acute Liver Failure.mSphere.2020;5(1):e00791-19.Published 2020Jan 29.doi:10.1128 / mSphere.00791–19
[0021] Materials 6:Yuan L,Li X,He S,Gao C,Wang C,Shao Y.Effects of NaturalFlavonoid Isoorientin on Growth Performance and Gut Microbiota of Mice.JAgric Food Chem.2018:66(37):9777–9784.doi:10.1021 / acs.jafc.8b03568
[0022] Non-patent literature 7: Huang P, Jiang A, Wang X, et al. NMN Maintains Intestinal Homeostasis by Regulating the Gut Microbiota. Front Nutr. 2021; 8: 714604. Published 2021 Jul 29. doi: 10.3389 / fnut.2021.714604
[0023] Non-patent document 8: Toscano M, De Grandi R, Stronati L, De Vecchi E, DragoL. Effect of Lactobacillus rhamnosus HN001 and Bifidobacterium longum BB536 on the healthy gut microbiota composition at phyla and species level: Apreliminary study. World J Gastroenterol.2017;23(15):2696-2704.doi:10.3748 / wjg.v23.i15.2696
[0024] Non-patent literature 9: Cheung SG, Goldenthal AR, Uhlemann AC, Mann JJ, Miller JM, Sublette ME. Systematic Review of Gut Microbiota and Major Depression. Front Psychiatry. 2019; 10: 34. Published 2019 Feb 11. doi: 10.3389 / fpsyt.2019.00034
[0025] Non-patent literature 10: Barandouzi ZA, Starkweather AR, Henderson WA, Gyamfi A, CongXS. Altered Composition of Gut Microbiota in Depression: A Systematic Review. Front Psychiatry. 2020; 11:541. Published 2020Jun 10. doi: 10.3389 / fpsyt.2020.00541
[0026] Non-patent literature 11: Xue J, Li X, Liu P, et al. Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiotain mice. Endocr J. 2019; 66(10): 859-870. doi: 10.1507 / endocrj.EJ18-0567
[0027] Non-patent literature 12: Yu ZT, Chen C, Newburg DS. Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gutmicrobes. Glycobiology. 2013; 23(11):1281-1292.doi:10.1093 / glycob / cwt065 Summary of the invention
[0028] Problem that the invention aims to solve
[0029] There is a desire for a new raw material that can inhibit the proliferation of intestinal bacteria, which are known to be involved in mental and behavioral disorders including mood disorders such as depression.
[0030] Solutions for solving problems
[0031] The present invention provides the following.
[0032] [1] A composition for controlling bacterial proliferation, comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides, wherein the bacteria are any species selected from the group consisting of Eggerthella bacteria, Oscillibacter bacteria, Holdemania bacteria and Parasutterella bacteria in the intestinal flora.
[0033] [2] A composition according to 1, which is used to control the growth of bacteria of the genus Eggerella, and comprises any one selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides containing lactose as a constituent sugar, human milk oligosaccharides containing fucose as a constituent sugar, lactose, and fucose.
[0034] [3] The composition according to 2, comprising any one selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose, and fucose.
[0035] [4] A composition according to 1, which is used to control the proliferation of any bacteria selected from the group consisting of Eggerella bacteria and Oscillocobacter bacteria, and the composition comprises any bacteria selected from the group consisting of fucosylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with fucose as a constituent sugar, lactose and fucose.
[0036] [5] The composition according to 4, comprising any one selected from the group consisting of 2'-fucosyllactose, lactose, and fucose.
[0037] [6] A composition according to 1, which is used to control the proliferation of any bacteria selected from the group consisting of Holdermanella bacteria and Parasutterella bacteria, and the composition comprises any bacteria selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with sialic acid as a constituent sugar, lactose and sialic acid.
[0038] [7] The composition according to item 6, comprising any one selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose, and N-acetylneuraminic acid.
[0039] [8] The composition according to any one of 1 to 7, which is used as a prebiotic or synbiotic.
[0040] [9] The composition according to any one of 1 to 8, which is used for the treatment of any one selected from the group consisting of depressive states and mood disorders.
[0041]
[10] A composition for treating a disease or condition improved by controlling the proliferation of bacteria, comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides, wherein the bacteria is any species selected from the group consisting of bacteria of the genus Eggerella, Oscillator bacteria, Holdermanella, and Parasutterella in the intestine.
[0042]
[11] A composition for treating any one selected from the group consisting of depressive states and mood disorders, comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0043]
[12] The composition according to any one of 1 to 10, wherein the proliferation control is proliferation inhibition.
[0044]
[13] A composition for use in a method for controlling the growth of any bacteria selected from the group consisting of Eggerella, Oscillator, Holdermanella, and Parasutterella in the intestinal flora, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition for controlling the growth of any bacteria selected from the group consisting of Eggerella, Oscillator, Holdermanella, and Parasutterella in the intestinal flora. A method or non-therapeutic method for controlling the growth of any bacteria selected from the group consisting of Eggerella, Oscillator, Holdermanella, and Parasutterella in the intestinal flora, comprising the step of administering a composition to a subject, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. A use or non-therapeutic use of a composition for controlling the proliferation of any bacteria selected from the group consisting of Eggertella, Oscillatoria, Holdermanella and Parasutterella in intestinal flora, wherein the composition comprises any bacteria selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0045]
[14] The composition according to item 13, for use in a method for controlling the proliferation of bacteria of the genus Eggerella, the composition comprising any one selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with fucose as a constituent sugar, lactose and fucose; The use in manufacturing according to item 13, wherein the composition is used for controlling the proliferation of bacteria of the genus Eggerella, the composition comprising any one selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with fucose as a constituent sugar, lactose and fucose. Fucose is any one of the group consisting of human milk oligosaccharides, lactose and fucose as constituent sugars; the method and non-therapeutic method according to 13, which includes the step of administering a composition to a subject, wherein the composition comprises any one of the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with fucose as a constituent sugar, lactose and fucose, and the composition is used to control the proliferation of bacteria of the genus Eggerella; or the use or non-therapeutic use of such a composition according to 13, which is used to control the proliferation of bacteria of the genus Eggerella.
[0046]
[15] A composition according to item 14, comprising any one selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose and fucose; use of any one selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose and fucose in the manufacture of item 14; a method or non-therapeutic method according to item 14, comprising the step of administering to a subject a composition comprising any one selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose and fucose; or the use or non-therapeutic use of such a composition according to item 14.
[0047]
[16] The composition according to item 13, which is used in a method for controlling the proliferation of any bacteria selected from the group consisting of bacteria of the genus Eggerella and Oscillocobacter, the composition comprising any one selected from the group consisting of fucosylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with fucose as a constituent sugar, lactose, and fucose; the use in manufacturing according to item 13, wherein the composition is any one selected from the group consisting of fucosylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with fucose as a constituent sugar, lactose, and fucose, and the composition is used to control the proliferation of bacteria selected from the group consisting of bacteria of the genus Eggerella. The method or non-therapeutic use of 13, which is used to control the proliferation of any bacteria selected from the group consisting of Eggerella bacteria and Oscillator bacteria; the method or non-therapeutic use of 13, which is used to control the proliferation of any bacteria selected from the group consisting of Eggerella bacteria and Oscillator bacteria.
[0048]
[17] A composition according to item 16, comprising any one selected from the group consisting of 2'-fucosyllactose, lactose and fucose; the use of any one selected from the group consisting of 2'-fucosyllactose, lactose and fucose in manufacturing according to item 16; a method or non-therapeutic method according to item 16, comprising the step of administering to a subject a composition comprising any one selected from the group consisting of 2'-fucosyllactose, lactose and fucose; or the use or non-therapeutic use of such a composition according to item 16.
[0049]
[18] A composition for use in a method for controlling the proliferation of any bacteria selected from the group consisting of bacteria of the genus Haldemannia and bacteria of the genus Parasutterella, the composition comprising any bacteria selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with sialic acid as a constituent sugar, lactose and sialic acid; use of any bacteria selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with sialic acid as a constituent sugar, lactose and sialic acid in the manufacture of a composition, the composition being used for controlling the proliferation of any bacteria selected from the group consisting of bacteria of the genus Haldemannia The invention relates to a method or non-therapeutic method for controlling the proliferation of any bacteria selected from the group consisting of Holdermanella bacteria and Parasutterella bacteria, comprising the step of administering a composition to a subject, wherein the composition comprises any one selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with sialic acid as a constituent sugar, lactose and sialic acid; or the use or non-therapeutic use of such a composition, wherein the composition is used to control the proliferation of any bacteria selected from the group consisting of Holdermanella bacteria and Parasutterella bacteria.
[0050]
[19] The composition according to item 18, comprising any one selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose, and N-acetylneuraminic acid; the use of any one selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose, and N-acetylneuraminic acid in manufacturing according to item 18; the method or non-therapeutic method according to item 18, comprising the step of administering to a subject a composition comprising any one selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose, and N-acetylneuraminic acid; or the use or non-therapeutic use of such a composition according to item 18.
[0051]
[20] The composition, use in manufacture, method or non-therapeutic method, or use or non-therapeutic use according to any one of 13 to 19, wherein the composition is used as a prebiotic or synbiotic.
[0052]
[21] A composition according to any one of 13 to 20, which is used in a method for treating any one selected from the group consisting of a depressive state and a mood disorder; the use in manufacturing according to any one of 13 to 20, wherein the composition is used to treat any one selected from the group consisting of a depressive state and a mood disorder; the method or non-therapeutic method according to any one of 13 to 20, which treats any one selected from the group consisting of a depressive state and a mood disorder; or the use or non-therapeutic use according to any one of 13 to 20, which is used to treat any one selected from the group consisting of a depressive state and a mood disorder.
[0053]
[22] A composition for use in a method for treating a disease or condition that is improved by controlling the growth of bacteria, wherein the bacteria is any species selected from the group consisting of bacteria of the genus Eggerella, Oscillator bacteria, Holdermanella, and Parasutterella in the intestine, and the composition comprises any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition, wherein the composition is used for treating a disease or condition that is improved by controlling the growth of bacteria, wherein the bacteria is any species selected from the group consisting of bacteria of the genus Eggerella, Oscillator bacteria, Holdermanella, and Parasutterella in the intestine; A method or non-therapeutic method for treating a disease or condition that is improved by controlling the growth of bacteria, comprising the step of administering to a subject a composition, wherein the composition comprises any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. The invention relates to a method for treating a disease or condition improved by controlling the proliferation of bacteria, wherein the bacterium is any species selected from the group consisting of Eggertella, Oscillator, Holdermanella and Parasutterella in the intestine; or a use or non-therapeutic use of a composition for treating a disease or condition improved by controlling the proliferation of bacteria, wherein the bacterium is any species selected from the group consisting of Eggertella, Oscillator, Holdermanella and Parasutterella in the intestine, and the composition comprises any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0054]
[23] A composition for use in a method for treating any species selected from the group consisting of depressive states and mood disorders, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides; use of any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition, the composition being used to treat any species selected from the group consisting of depressive states and mood disorders; a method or non-therapeutic method for treating any species selected from the group consisting of depressive states and mood disorders, comprising the step of administering a composition to a subject, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides; or a use or non-therapeutic use of a composition for treating any species selected from the group consisting of depressive states and mood disorders, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0055]
[24] The composition, use in manufacture, method or non-therapeutic method, or use or non-therapeutic use according to any one of 13 to 22, wherein proliferation control is proliferation inhibition.
[0056] The present invention provides as follows:
[0057] [1] A composition for controlling the proliferation of bacteria of the genus Eggerthella in intestinal flora, comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0058] [2] The composition according to item 1, comprising any one selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides containing lactose as a constituent sugar, human milk oligosaccharides containing fucose as a constituent sugar, lactose, and fucose.
[0059] [3] The composition according to 1 or 2, comprising any one selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose, and fucose.
[0060] [4] The composition according to any one of 1 to 3, which is used as a prebiotic or synbiotic.
[0061] [5] A composition according to any one of 1 to 4, which is used for the treatment of any type selected from the group consisting of inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, mood disorders and asthma, or for administration to patients with colitis exacerbated by activation of helper T17 cells, or for administration to patients with heart failure and arrhythmia taking digoxin.
[0062] [6] A composition for treating a disease or condition that is improved by controlling the proliferation of bacteria of the genus Eggerella in the intestine, comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0063] [7] A composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides, the composition being used for the treatment of any one selected from the group consisting of inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, mood disorders and asthma, or for administration to patients with colitis exacerbated by activation of helper T17 cells, or for administration to patients with heart failure and arrhythmia taking digoxin.
[0064] [8] The composition according to any one of 1 to 6, wherein the proliferation control is proliferation inhibition.
[0065] [9] A composition for use in a method for controlling the proliferation of bacteria of the genus Eggerella in intestinal flora, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition, the composition controlling the proliferation of bacteria of the genus Eggerella in intestinal flora. A method for controlling the proliferation of bacteria of the genus Eggerella in intestinal flora, comprising the step of administering a composition to a subject, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of a composition for controlling the proliferation of bacteria of the genus Eggerella in intestinal flora, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0066]
[10] A composition according to 9, comprising any one selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with fucose as a constituent sugar, lactose and fucose; or the use, method, or use of such a composition in manufacturing according to 9.
[0067]
[11] The composition according to 9 or 10, comprising any one selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose and fucose; or the use, method, or use of such a composition in manufacturing according to 9 or 10.
[0068]
[12] A composition according to any one of 9 to 11, which is used as a prebiotic or synbiotic; the use of such a composition in manufacturing according to any one of 9 to 11; a method according to any one of 9 to 11, which includes the step of administering the composition as a prebiotic or synbiotic; or the use according to any one of 9 to 11 as a prebiotic or synbiotic.
[0069]
[13] A composition according to any one of 9 to 12, which is used for the treatment of any one selected from the group consisting of inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, mood disorders and asthma, or is used for administration to patients with colitis aggravated by activation of helper T17 cells, or is used for administration to patients with heart failure and arrhythmia taking digoxin; the use of such a composition in manufacturing according to any one of 9 to 12; the method according to any one of 9 to 12, which is used for the treatment of any one selected from the group consisting of inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, mood disorders and asthma, or is used for administration to patients with colitis aggravated by activation of helper T17 cells, or is used for administration to patients with heart failure and arrhythmia taking digoxin; or the use according to any one of 9 to 12 for such treatment.
[0070]
[14] A composition for treating a disease or condition that can be improved by controlling the proliferation of bacteria of the genus Eggerella in the intestine, comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition, the composition being used for treating a disease or condition that can be improved by controlling the proliferation of bacteria of the genus Eggerella in the intestine. A method for treating a disease or condition that can be improved by controlling the proliferation of bacteria of the genus Eggerella in the intestine, comprising the step of administering a composition to a subject, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of a composition for treating a disease or condition that can be improved by controlling the proliferation of bacteria of the genus Eggerella in the intestine, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0071]
[15] A composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides, the composition being used for the treatment of any one selected from the group consisting of inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, mood disorders and asthma, or for administration to patients with colitis aggravated by activation of helper T17 cells, or for administration to patients with heart failure and arrhythmia taking digoxin. Use of any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition, the composition being used for the treatment of any one selected from the group consisting of inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, mood disorders and asthma, or for administration to patients with colitis aggravated by activation of helper T17 cells, or for administration to patients with heart failure and arrhythmia taking digoxin. A method, comprising the step of administering to a subject a composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides, the method being used for the treatment of any one selected from the group consisting of inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, mood disorders, and asthma, or for administration to patients with colitis aggravated by activation of helper T17 cells, or for administration to patients with heart failure and arrhythmia taking digoxin. A use of a composition, for the treatment of any one selected from the group consisting of inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, mood disorders, and asthma, or for administration to patients with colitis aggravated by activation of helper T17 cells, or for administration to patients with heart failure and arrhythmia taking digoxin, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0072]
[16] The composition, use in the manufacture of a composition, method, or use according to any one of 9 to 14, wherein the proliferation control is proliferation inhibition.
[0073] The present invention provides as follows:
[0074] [1] A composition for controlling the proliferation of Oscillibacter bacteria in intestinal flora, comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0075] [2] The composition according to item 1, comprising any one selected from the group consisting of fucosylated human milk oligosaccharides, human milk oligosaccharides containing lactose as a constituent sugar, human milk oligosaccharides containing fucose as a constituent sugar, lactose, and fucose.
[0076] [3] The composition according to 1 or 2, comprising any one selected from the group consisting of 2'-fucosyllactose, lactose, and fucose.
[0077] [4] The composition according to any one of 1 to 3, which is used as a prebiotic or synbiotic.
[0078] [5] The composition according to any one of 1 to 4, which is used for the treatment of any one selected from the group consisting of chronic kidney disease, mood disorders and inflammatory bowel disease.
[0079] [6] A composition for treating a disease or condition that is improved by controlling the proliferation of bacteria of the genus Oscillator in the intestinal tract, comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0080] [7] A composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides, the composition being used for the treatment of any one selected from the group consisting of chronic kidney disease, mood disorders, and inflammatory bowel disease.
[0081] [8] The composition according to any one of 1 to 6, wherein the proliferation control is proliferation inhibition.
[0082] [9] A composition for use in a method for controlling the proliferation of Oscillation Bacteria in intestinal flora, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition, the composition controlling the proliferation of Oscillation Bacteria in intestinal flora. A method for controlling the proliferation of Oscillation Bacteria in intestinal flora, comprising the step of administering a composition to a subject, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of a composition for controlling the proliferation of Oscillation Bacteria in intestinal flora, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0083]
[10] A composition according to 9, comprising any one selected from the group consisting of fucosylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with fucose as a constituent sugar, lactose and fucose; or the use, method, or use of such a composition in manufacturing according to 9.
[0084]
[11] The composition according to 9 or 10, comprising any one selected from the group consisting of 2'-fucosyllactose, lactose and fucose; or the use, method, or use of such composition in manufacturing according to 9 or 10.
[0085]
[12] A composition according to any one of 9 to 11, which is used as a prebiotic or synbiotic; the use of such a composition in manufacturing according to any one of 9 to 11; a method according to any one of 9 to 11, which includes the step of administering the composition as a prebiotic or synbiotic; or the use according to any one of 9 to 11 as a prebiotic or synbiotic.
[0086]
[13] A composition according to any one of 9 to 12, which is used for the treatment of any one of the group consisting of chronic kidney disease, mood disorders and inflammatory bowel disease; the use of such a composition in manufacturing according to any one of 9 to 12; a method according to any one of 9 to 12, which is used for the treatment of any one of the group consisting of chronic kidney disease, mood disorders and inflammatory bowel disease; or the use according to any one of 9 to 12 for such treatment.
[0087]
[14] A composition for treating a disease or condition that can be improved by controlling the proliferation of Oscillibacter bacteria in the intestine, comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition, the composition being used for treating a disease or condition that can be improved by controlling the proliferation of Oscillibacter bacteria in the intestine. A method for treating a disease or condition that can be improved by controlling the proliferation of Oscillibacter bacteria in the intestine, comprising the step of administering a composition to a subject, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of a composition for treating a disease or condition that can be improved by controlling the proliferation of Oscillibacter bacteria in the intestine, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0088]
[15] A composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides, the composition being used for treating any one selected from the group consisting of chronic kidney disease, mood disorders and inflammatory bowel disease. Use of any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition, the composition being used for treating any one selected from the group consisting of chronic kidney disease, mood disorders and inflammatory bowel disease. A method for treating any one selected from the group consisting of chronic kidney disease, mood disorders and inflammatory bowel disease, comprising the step of administering a composition to a subject, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of a composition for treating any one selected from the group consisting of chronic kidney disease, mood disorders and inflammatory bowel disease, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0089]
[16] The composition, use in the manufacture of a composition, method, or use according to any one of 9 to 14, wherein the proliferation control is proliferation inhibition.
[0090] The present invention provides as follows:
[0091] [1] A composition for controlling the proliferation of bacteria of the genus Holdemania in intestinal flora, comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0092] [2] The composition according to item 1, comprising any one selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides containing lactose as a constituent sugar, human milk oligosaccharides containing sialic acid as a constituent sugar, lactose, and sialic acid.
[0093] [3] The composition according to 1 or 2, comprising any one selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose, and N-acetylneuraminic acid.
[0094] [4] The composition according to any one of 1 to 3, which is used as a prebiotic or synbiotic.
[0095] [5] The composition according to any one of 1 to 4, which is used for the treatment of any one selected from the group consisting of mood disorders and Parkinson's disease.
[0096] [6] A composition for treating a disease or condition that can be improved by controlling the proliferation of bacteria of the genus Holdermanella in the intestine, comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0097] [7] A composition for treating any disease selected from the group consisting of mood disorders and Parkinson's disease, comprising any disease selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0098] [8] The composition according to any one of 1 to 6, wherein the proliferation control is proliferation inhibition.
[0099] [9] A composition for use in a method for controlling the proliferation of bacteria of the genus Holdermanella in intestinal flora, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition, the composition controlling the proliferation of bacteria of the genus Holdermanella in intestinal flora. A method for controlling the proliferation of bacteria of the genus Holdermanella in intestinal flora, comprising the step of administering a composition to a subject, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of a composition for controlling the proliferation of bacteria of the genus Holdermanella in intestinal flora, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0100]
[10] A composition according to 9, comprising any one selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with sialic acid as a constituent sugar, lactose and sialic acid; or the use, method, or use of such a composition in manufacturing according to 9.
[0101]
[11] The composition according to 9 or 10, which comprises any one selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose and N-acetylneuraminic acid; or the use, method, or use of such a composition in manufacturing according to 9 or 10.
[0102]
[12] A composition according to any one of 9 to 11, which is used as a prebiotic or synbiotic; the use of such a composition in manufacturing according to any one of 9 to 11; a method according to any one of 9 to 11, which includes the step of administering the composition as a prebiotic or synbiotic; or the use according to any one of 9 to 11 as a prebiotic or synbiotic.
[0103]
[13] A composition according to any one of 9 to 12, which is used for the treatment of any type selected from the group consisting of mood disorders and Parkinson's disease; the use of such a composition in manufacturing according to any one of 9 to 12; a method according to any one of 9 to 12, which is used for the treatment of any type selected from the group consisting of mood disorders and Parkinson's disease; or the use according to any one of 9 to 12 for such treatment.
[0104]
[14] A composition for treating a disease or condition that can be improved by controlling the growth of Holdermanella bacteria in the intestine, comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition for treating a disease or condition that can be improved by controlling the growth of Holdermanella bacteria in the intestine. A method for treating a disease or condition that can be improved by controlling the growth of Holdermanella bacteria in the intestine, comprising the step of administering a composition to a subject, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of a composition for treating a disease or condition that can be improved by controlling the growth of Holdermanella bacteria in the intestine, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0105]
[15] A composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides, the composition being used for treating any one selected from the group consisting of mood disorders and Parkinson's disease. Use of any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition, the composition being used for treating any one selected from the group consisting of mood disorders and Parkinson's disease. A method for treating any one selected from the group consisting of mood disorders and Parkinson's disease, comprising the step of administering a composition to a subject, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of a composition for treating any one selected from the group consisting of mood disorders and Parkinson's disease, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0106]
[16] The composition, use in the manufacture of a composition, method, or use according to any one of 9 to 14, wherein the proliferation control is proliferation inhibition.
[0107] The present invention provides as follows:
[0108] [1] A composition for controlling the proliferation of Parasutterella bacteria in intestinal flora, comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0109] [2] The composition according to item 1, comprising any one selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides containing lactose as a constituent sugar, human milk oligosaccharides containing sialic acid as a constituent sugar, lactose, and sialic acid.
[0110] [3] The composition according to 1 or 2, comprising any one selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose, and N-acetylneuraminic acid.
[0111] [4] The composition according to any one of 1 to 3, which is used as a prebiotic or synbiotic.
[0112] [5] The composition according to any one of 1 to 4, which is used for treating any one selected from the group consisting of mood disorders, irritable bowel syndrome and liver dysfunction.
[0113] [6] A composition for treating a disease or condition that can be improved by controlling the proliferation of Parasutterella bacteria in the intestine, comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0114] [7] A composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides, the composition being used for treating any one selected from the group consisting of mood disorders, irritable bowel syndrome and liver dysfunction.
[0115] [8] The composition according to any one of 1 to 6, wherein the proliferation control is proliferation inhibition.
[0116] [9] A composition for use in a method for controlling the proliferation of Parasartella bacteria in intestinal flora, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition, the composition controlling the proliferation of Parasartella bacteria in intestinal flora. A method for controlling the proliferation of Parasartella bacteria in intestinal flora, comprising the step of administering a composition to a subject, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of a composition for controlling the proliferation of Parasartella bacteria in intestinal flora, the composition comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0117]
[10] A composition according to 9, comprising any one selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with sialic acid as a constituent sugar, lactose and sialic acid; or the use, method, or use of such a composition in manufacturing according to 9.
[0118]
[11] The composition according to 9 or 10, which comprises any one selected from the group consisting of 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lactose and N-acetylneuraminic acid; or the use, method, or use of such a composition in manufacturing according to 9 or 10.
[0119]
[12] A composition according to any one of 9 to 11, which is used as a prebiotic or synbiotic; the use of such a composition in manufacturing according to any one of 9 to 11; a method according to any one of 9 to 11, which includes the step of administering the composition as a prebiotic or synbiotic; or the use according to any one of 9 to 11 as a prebiotic or synbiotic.
[0120]
[13] A composition according to any one of 9 to 12, which is used for the treatment of any one selected from the group consisting of mood disorders, irritable bowel syndrome and liver dysfunction; the use of such a composition in manufacturing according to any one of 9 to 12; a method according to any one of 9 to 12, which is used for the treatment of any one selected from the group consisting of mood disorders, irritable bowel syndrome and liver dysfunction; or the use according to any one of 9 to 12 for such treatment.
[0121]
[14] A composition for treating a disease or condition that can be improved by controlling the proliferation of Parasartella bacteria in the intestine, comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition, the composition being used for treating a disease or condition that can be improved by controlling the proliferation of Parasartella bacteria in the intestine. A method for treating a disease or condition that can be improved by controlling the proliferation of Parasartella bacteria in the intestine, comprising the step of administering a composition to a subject, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of a composition for treating a disease or condition that can be improved by controlling the proliferation of Parasartella bacteria in the intestine, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0122]
[15] A composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides, the composition being used for treating any one selected from the group consisting of mood disorders, irritable bowel syndrome and liver dysfunction. Use of any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides in the manufacture of a composition, the composition being used for treating any one selected from the group consisting of mood disorders, irritable bowel syndrome and liver dysfunction. A method for treating any one selected from the group consisting of mood disorders, irritable bowel syndrome and liver dysfunction, comprising the step of administering a composition to a subject, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides. Use of a composition for treating any one selected from the group consisting of mood disorders, irritable bowel syndrome and liver dysfunction, the composition comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
[0123]
[16] The composition, use in the manufacture of a composition, method, or use according to any one of 9 to 14, wherein the proliferation control is proliferation inhibition.
[0124] Effects of the Invention
[0125] According to the present invention, it is possible to control the intestinal flora, and in particular, it is possible to control the growth of bacteria of the genus Eggerella, bacteria of the genus Oscillator, bacteria of the genus Holdermanella, and bacteria of the genus Parasutterella, and the increase in the occupancy rate in the flora.
[0126] By controlling the proliferation of Eggerthella bacteria and the increase in their occupancy rate in the intestinal flora using a specific active ingredient, it is possible to treat any of the group consisting of inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, mood disorders, and asthma, and it can be given to patients with colitis that is aggravated by activation of helper T17 cells, or to patients with heart failure and arrhythmia who are taking digoxin. In addition, according to the present invention, it is expected that various diseases or conditions that can be improved by controlling the increase of Eggerthella bacteria in the intestinal flora can be treated.
[0127] By controlling the proliferation of Oscillator bacteria and the increase in their occupancy rate in the intestinal flora using a specific active ingredient, any disease selected from the group consisting of chronic kidney disease, mood disorders, and inflammatory bowel disease can be treated. In addition, according to the present invention, it is expected that various diseases or conditions that can be improved by controlling the increase of Oscillator bacteria in the intestinal flora can be treated.
[0128] By controlling the proliferation of the bacteria of the genus Haldemannia and the increase in the occupancy rate in the intestinal flora with a specific active ingredient, any disease selected from the group consisting of mood disorders and Parkinson's disease can be treated. In addition, according to the present invention, it is expected that various diseases or conditions that can be improved by controlling the increase of the bacteria of the genus Haldemannia in the intestinal flora can be treated.
[0129] By controlling the growth of Parasutterella bacteria and the increase in their occupancy rate in the intestinal flora using a specific active ingredient, it is possible to treat any of the following selected from the group consisting of mood disorders, irritable bowel syndrome, and liver dysfunction. In addition, according to the present invention, it is expected that various diseases or conditions that can be improved by controlling the increase of Parasutterella bacteria in the intestinal flora can be treated.
[0130] By adding the active ingredient of the present invention, various forms of functional foods can be provided. BRIEF DESCRIPTION OF THE DRAWINGS
[0131] Figure 1 Changes in the occupancy of Eggerella bacteria caused by various sugars in the human feces culture system were analyzed using the Wilcoxon signed rank test.
[0132] Figure 2 Changes in the occupancy of Oscillator bacteria caused by various sugars in human fecal culture systems were analyzed using the Wilcoxon signed-rank test or paired t-test.
[0133] Figure 3Changes in the occupancy of Oscillator bacteria due to fucose in human fecal culture systems. Wilcoxon signed-rank test.
[0134] Figure 4 Changes in the occupancy of the genus Holdermanella in response to various sugars in the human fecal culture system were analyzed using paired t-test or Wilcoxon signed-rank test.
[0135] Figure 5 Changes in the occupancy of Parasatella bacteria in response to various sugars in a human fecal culture system. Wilcoxon signed-rank test.
[0136] Figure 6 Changes in the occupancy of Parasutterella bacteria caused by 6'-SL in a human fecal culture system. Paired t-test was used. DETAILED DESCRIPTION
[0137] Hereinafter, the present invention will be described in detail.
[0138] The present invention relates to a composition for controlling the proliferation of bacteria, which contains any species selected from the group consisting of human milk oligosaccharides (also called HMOs) and constituent sugars of human milk oligosaccharides as an active ingredient, wherein the bacteria are bacteria of the genus Eggerella, Oscillator bacteria, and Parasutterella in the intestinal flora.
[0139] [Active ingredients]
[0140] The composition of the present invention comprises any one selected from the group consisting of human milk oligosaccharides (also referred to as HMO) and constituent sugars of human milk oligosaccharides as an active ingredient. Human milk oligosaccharides are oligosaccharides contained in human milk and are the third most abundant solid component after lactose and lipids. With a few exceptions, human milk oligosaccharides have a chemical structure having a lactose unit on the reducing end side and fucose, sialic acid, galactose, etc. added thereto.
[0141] It should be noted that, in the present invention, the abbreviations and structures of milk oligosaccharides follow Nutr Rev. 2017 Nov 1; 75(11): 920-933. doi: 10.1093 / nutrit / nux044. and Nutrients 2021, 13(8), 2737; https: / / doi.org / 10.3390 / nu13082737. If there is a disagreement between these documents, the latter shall be followed.
[0142] The human milk oligosaccharides and the constituent sugars of human milk oligosaccharides used in the composition are not particularly limited as long as they have the intended effect. In addition, the human milk oligosaccharides and the constituent sugars of human milk oligosaccharides used in the composition may be one type or a combination of two or more types.
[0143] Examples of the human milk oligosaccharide contained in the composition include the following neutral oligosaccharides and acidic oligosaccharides.
[0144] Neutral oligosaccharides: 2'-fucosyllactose (2'-FL), 3-fucosyllactose (3-FL), difucosyllactose (Lacto-difucotetraose) (DFL, LDFT), lactose-N-tetraose (LNT), lactose-N-neotetraose (LNnT), lactose-N-fucopentaose I (LNFP I), lactose-N-fucopentaose II (LNFP II), lactose-N-fucopentaose III (LNFP III), lactose-N-fucopentaose V (LNFP V), lactose-N-fucopentaose VI (LNFP VI), lactose-N-difucohexaose I (LNDFHI), lactose-N-difucohexaose II (LNDFH II), lactose-N-hexaose (LNH), para-lactose-N-hexaose (pLNH), lactose-N-neohexose (LNnH), para-lactose-N-neohexose (pLNnH), fucosyllactose-N-hexaose I (F-LNH I), fucosyl-para-lactose-N-hexaose I (F-para-LNH I), fucosyllactose-N-hexaose II (F-LNH II), fucosyl-lactose-N-hexaose III (F-LNH III), difucosyl-lactose-N-hexaose I (DF-LNH I), difucosyl-lactose-N-hexaose II (DF-LNH II), difucosyl-lactose-N-hexaose III (DF-LNH III), difucosyl-p-lactose-N-neohexose (DF-pLNnH), difucosyl-p-lactose-N-hexaose (DF-para-LNH), difucosyl-p-lactose-N-neohexose (DF-para-LNnH), trifucosyl-lactose-N-hexaose (TF-LNH).
[0145] Acidic oligosaccharides: 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), 6'-sialyllactose-N-acetyllactosamine (6'-SLN), LS-tetrasaccharide a (sialyllactose-N-tetrasaccharide a) (LST a), LS-tetrasaccharide b (sialyllactose-N-tetrasaccharide b) (LST b), LS-tetrasaccharide c (sialyllactose-N-tetrasaccharide c) (LST c), disialyllactose-N-tetrasaccharide (DS-LNT), fucosyl-sialyllactose-N-tetrasaccharide a (F-LST a), fucosyl-sialyllactose-N-tetrasaccharide b (F-LST b), fucosyl-sialyllactose-N-hexasaccharide (FS-LNH), fucosyl-sialyllactose-N-neohexacharide (FS-LNNH I), fucosyl-disialyl lactose-N-hexaose (FDS-LNH), disialyl lactose-N-hexaose (DS-LNH).
[0146] Preferred examples of the human milk oligosaccharide contained in the composition include the following neutral oligosaccharides and acidic oligosaccharides.
[0147] Neutral oligosaccharides: 2'-fucosyllactose (2'-FL), 3-fucosyllactose (3-FL), difucosyllactose (lactose-difucotetraose) (DFL, LDFT), lactose-N-tetraose (LNT), lactose-N-neotetraose (LNnT), lactose-N-fucopentaose I (LNFP I), lactose-N-fucopentaose II (LNFP II), lactose-N-fucopentaose III (LNFP III), lactose-N-fucopentaose V (LNFP V), lactose-N-fucopentaose VI (LNFP VI), lactose-N-difucohexaose I (LNDFH I), lactose-N-difucohexaose II (LNDFH II), lactose-N-hexaose (LNH), lactose-N-neohexose (LNnH), para-lactose-N-neohexose (pLNnH), fucosyllactose-N-hexaose I (F-LNH I), fucosyl-para-lactose-N-hexaose I (F-para-LNHI), fucosyllactose-N-hexaose II (F-LNH II), fucosyllactose-N-hexaose III (F-LNH III), difucosyllactose-N-hexaose I (DF-LNH I), difucosyllactose-N-hexaose II (DF-LNH II), difucosyllactose-N-hexaose III (DF-LNH III), difucosyllactose-para-lactose-N-neohexose (DF-pLNnH), trifucosyllactose-N-hexaose (TF-LNH).
[0148] Acidic oligosaccharides: 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), LS-tetrasaccharide a (sialyllactose-N-tetrasaccharide a) (LST a), LS-tetrasaccharide b (sialyllactose-N-tetrasaccharide b) (LST b), LS-tetrasaccharide c (sialyllactose-N-tetrasaccharide c) (LST c), disialyllactose-N-tetrasaccharide (DS-LNT), fucosyl-sialyllactose-N-neohexaose (FS-LNnH I), disialyllactose-N-hexaose (DS-LNH).
[0149] More preferred examples of the human milk oligosaccharide contained in the composition include the following neutral oligosaccharides and acidic oligosaccharides.
[0150] Neutral oligosaccharides: 2'-fucosyllactose (2'-FL), difucosyllactose (lactose-difucotetraose) (DFL, LDFT), lactose-N-tetraose (LNT), lactose-N-neotetraose (LNnT)
[0151] Acidic oligosaccharides: 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL)
[0152] In the present invention, when referring to the constituent sugars of human milk oligosaccharides, it means: sugars constituting human milk oligosaccharides (sugars produced by the decomposition of human milk oligosaccharides) excluding glucose and galactose. Examples of the constituent sugars of human milk oligosaccharides contained in the composition include lactose, fucose, sialic acid, and N-acetylglucosamine. Sialic acid is a general term for modified forms of neuraminic acid. As an example of sialic acid, N-acetylneuraminic acid (Neu5Ac) formed by modifying neuraminic acid with an acetyl group can be listed.
[0153] According to the research of the inventors, it is confirmed that lactose, fucose, 2'-FL, 3'-SL, and 6'-SL have excellent proliferation inhibitory effects on bacteria of the genus Eggerella. Here, human milk oligosaccharides can produce lactose in the human digestive tract after ingestion. In addition, human milk oligosaccharides containing fucose as a constituent sugar can produce fucose in the human digestive tract after ingestion (refer to non-patent documents 13 and 14 described later). Furthermore, it has been confirmed that 2'-FL, 3'-SL, and 6'-SL all have the target effect. Therefore, as long as they are fucosylated human milk oligosaccharides and sialylated human milk oligosaccharides, the target effect can be fully obtained.
[0154] From this viewpoint, preferred examples of human milk oligosaccharides and constituent sugars of human milk oligosaccharides used in the composition are any selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides containing lactose as a constituent sugar, human milk oligosaccharides containing fucose as a constituent sugar, lactose, and fucose. Human milk oligosaccharides containing fucose as a constituent sugar include fucosylated human milk oligosaccharides (e.g., 2'-FL) and fucose-containing human milk oligosaccharides (e.g., DFL (LDFT)).
[0155] Specific examples of the human milk oligosaccharide and the constituent sugar of the human milk oligosaccharide used in the composition are any selected from the group consisting of 2′-FL, 3′-SL, 6′-SL, lactose, and fucose.
[0156] According to the research of the present inventors, it was confirmed that lactose, fucose, and 2'-FL have excellent growth inhibition effects on bacteria of the genus Oscillator. Here, human milk oligosaccharides can produce lactose in the human digestive tract after ingestion. In addition, human milk oligosaccharides containing fucose as a constituent sugar can produce Neu5Ac and fucose in the human digestive tract respectively after ingestion (see non-patent documents 13, 14 described below). It has been confirmed that 2'-FL has the target effect, so as long as it is fucosylated human milk oligosaccharides, the target effect can be fully obtained.
[0157] From this viewpoint, preferred examples of human milk oligosaccharides and constituent sugars of human milk oligosaccharides used in the composition are any selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides containing lactose as a constituent sugar, human milk oligosaccharides containing fucose as a constituent sugar, lactose, and fucose. Human milk oligosaccharides containing fucose as a constituent sugar include fucosylated human milk oligosaccharides (e.g., 2'-FL) and fucose-containing human milk oligosaccharides (e.g., DFL (LDFT)).
[0158] Specific examples of the human milk oligosaccharide and the constituent sugar of the human milk oligosaccharide used in the composition are any selected from the group consisting of 2′-FL, lactose, and fucose.
[0159] According to the research conducted by the inventors, it has been confirmed that lactose, Neu5Ac, 2'-FL, 3'-SL, and 6'-SL have excellent growth inhibition effects on Holdermanella bacteria. Here, human milk oligosaccharides can produce lactose in the human digestive tract after ingestion. In addition, human milk oligosaccharides containing Neu5Ac as a constituent sugar can produce Neu5Ac in the human digestive tract after ingestion (see non-patent documents 13, 15, and 16 described below). Furthermore, it has been confirmed that 2'-FL, 3'-SL, and 6'-SL all have the target effect, so as long as they are fucosylated human milk oligosaccharides and sialylated human milk oligosaccharides, the target effect can be fully obtained.
[0160] From this viewpoint, preferred examples of human milk oligosaccharides and constituent sugars of human milk oligosaccharides used in the composition are any selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with sialic acid as a constituent sugar, lactose, and sialic acid. Human milk oligosaccharides with sialic acid as a constituent sugar include sialylated human milk oligosaccharides (e.g., 3'-SL, 6'-SL), and sialic acid-containing human milk oligosaccharides (e.g., LST a, DS-LNT).
[0161] Specific examples of the human milk oligosaccharide and the constituent sugar of the human milk oligosaccharide used in the composition include any one selected from the group consisting of 2′-FL, 3′-SL, 6′-SL, lactose, and Neu5Ac.
[0162] According to the research of the inventors, it is confirmed that lactose, Neu5Ac, 2'-FL, 3'-SL, and 6'-SL have excellent proliferation inhibition effects on Parasartella bacteria. Here, human milk oligosaccharides can produce lactose in the human digestive tract after ingestion. In addition, human milk oligosaccharides containing Neu5Ac as a constituent sugar can produce Neu5Ac in the human digestive tract after ingestion (refer to non-patent documents 13, 15, and 16 described below). Furthermore, it has been confirmed that 2'-FL, 3'-SL, and 6'-SL all have the target effect. Therefore, as long as they are fucosylated human milk oligosaccharides and sialylated human milk oligosaccharides, the target effect can be fully obtained.
[0163] From this viewpoint, preferred examples of human milk oligosaccharides and constituent sugars of human milk oligosaccharides used in the composition are any selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides with lactose as a constituent sugar, human milk oligosaccharides with sialic acid as a constituent sugar, lactose, and sialic acid. Human milk oligosaccharides with sialic acid as a constituent sugar include sialylated human milk oligosaccharides (e.g., 3'-SL, 6'-SL), and sialic acid-containing human milk oligosaccharides (e.g., LST a, DS-LNT).
[0164] Specific examples of the human milk oligosaccharide and the constituent sugar of the human milk oligosaccharide used in the composition include any one selected from the group consisting of 2′-FL, 3′-SL, 6′-SL, lactose, and Neu5Ac.
[0165] [use]
[0166] The composition of the present invention can be used to control the proliferation of bacteria in the intestinal flora, which are known to be associated with mental and behavioral disorders. The composition of the present invention can be used to control the proliferation of any bacteria selected from the group consisting of Eggerthella bacteria, Oscillator bacteria, Holdermanella bacteria, and Parasutterella bacteria in the intestinal flora. Proliferation control includes proliferation promotion and proliferation inhibition. The preferred composition is used for proliferation inhibition.
[0167] Examples of bacteria contained in the intestinal flora include the following:
[0168] Bacteria of the genus Faecalibacterium, for example, Faecalibacterium prausnitzii;
[0169] Bacteria of the genus Akkermansia, for example Akkermansia muciniphila;
[0170] Bacteria of the genus Blautia, for example Blautia coccoides, Blautia intestinalis, Blautia faecicola;
[0171] Bacteria of the genus Subdoligranulum, for example Subdoligranulumvariabile;
[0172] Bacteria of the genus Bilophila, for example, Bilophila wadsworthia;
[0173] Bacteria of the genus Collinsella, for example, Collinsella aerofaciens and Collinsella intestinalis;
[0174] Bacteria of the genus Holdemania, for example, Holdemania filiformis;
[0175] Bacteria of the genus Parasutterella, for example, Parasutterella excrementihominis, Parasutterella secunda;
[0176] Oscillibacter bacteria, such as Oscillibacter valericigenes;
[0177] Bacteria of the genus Eggerthella, for example Eggerthella lenta;
[0178] Bacteria of the genus Sutterella, for example, Sutterella parvirubra, Sutterella wadsworthensis;
[0179] Bacteria of the genus Bifidobacterium (bifidobacteria), for example, Bifidobacterium adolescentis (B. adolescentis), Bifidobacterium bifidum (B. bifidum), Bifidobacterium breve (B. breve), Bifidobacterium catenulatum (B. catenulatum), Bifidobacterium infantis (B. infantis), Bifidobacterium lactis (B. lactis), Bifidobacterium longum (B. longum), Bifidobacterium pseudocatenulatum (B. pseudocatenulatum).
[0180] In relation to the present invention, when referring to bacteria of the genus Eggerella, it refers to bacteria identified as Eggerella by molecular phylogenetic analysis based on the 16S rRNA gene. In relation to the present invention, when referring to bacteria of the genus Oscillator, it refers to bacteria identified as Oscillator by molecular phylogenetic analysis based on the 16S rRNA gene. In relation to the present invention, when referring to bacteria of the genus Haldemania, it refers to bacteria identified as Haldemania by molecular phylogenetic analysis based on the 16S rRNA gene. In relation to the present invention, when referring to bacteria of the genus Parasartella, it refers to bacteria identified as Parasartella by molecular phylogenetic analysis based on the 16S rRNA gene. The standard for determining the genus of bacteria by molecular phylogenetic analysis based on the 16S rRNA gene is well known to those skilled in the art (Stackebrandt E, Ebers J. Taxonomic parameters revisited: tarnished gold standards. Microbiol Today 2006; 33: 152-155.).
[0181] In the present invention, controlling the growth of specific bacteria in the bacterial flora means controlling the ratio (occupancy rate) of the specific bacteria in the bacterial flora.
[0182] Whether a certain component controls the proliferation of specific bacteria in the intestinal flora can be evaluated as follows. Add feces provided by a healthy person to a suitable culture medium, culture for a certain period of time as needed, add the component to be evaluated, culture under suitable conditions (for example, culture for 48 hours at 37°C and anaerobic conditions similar to the conditions in the intestine), and measure the occupancy rate of specific bacteria in the flora in the culture. Then, compare the measurement results with the measurement results of a culture cultured under the same conditions that differs only in that a control (such as sterilized water) is added instead of the component to be evaluated. When the occupancy rate is higher than the control, it can be judged that the proliferation is promoted, and when the occupancy rate is lower than the control, it can be judged that the proliferation is inhibited.
[0183] The occupancy rate of a specific bacterium contained in the bacterial community can be determined by a known method. One of the preferred methods is to perform 16S metagenomic analysis (sequence analysis of 16S rRNA gene amplicons) on DNA extracted from the culture. In the case of implementing 16S metagenomic analysis, DNA extraction can be performed using a commercially available kit. The genomic region analyzed is not particularly limited as long as the bacteria can be identified, but the V3-V4 region of the 16S rRNA gene can be used. Methods such as primers, amplification conditions, and purification of amplicons used for bacterial analysis can also use methods familiar to those skilled in the art. Sequence interpretation is preferably performed using a next-generation sequencer with higher performance. The resulting data can be analyzed using QIIME 2 TM For 16S metagenomic analysis, those skilled in the art can refer to Sanschagrin S, Yergeau E. Next-generation sequencing of 16S ribosomal RNA geneamplicons. J Vis Exp. 2014; (90): 51709. Published 2014 Aug 29. doi: 10.3791 / 51709 and other information.
[0184] It is reported that intestinal bacteria are related to mood disorders such as depression. For example, it is reported that the result of giving feces of patients with depression and healthy people to sterile mice shows that the depressive-like behavior of mice given feces of patients with depression increases compared with mice given feces of healthy people (the aforementioned non-patent literature 1). In addition, in a systematic review of intestinal bacteria comparing healthy people and patients with depression, it is reported that in patients with depression, there are more intestinal bacteria of a total of 24 genera headed by bacteria of the genus Egger, bacteria of the genus Oscillator, bacteria of the genus Holderman, and bacteria of the genus Parasartella (the aforementioned non-patent literature 2). Therefore, the composition of the present invention that can control the proliferation of specific intestinal bacteria can be used to dispose of any species selected from the group consisting of depressive state and mood disorder.
[0185] The bacteria of the genus Eggerella involved in the present invention are a kind of common bacteria in the human intestine, but in recent years, they have been reported to be related to various diseases. For example, it is reported that the genus Eggerella has a high incidence in patients with inflammatory bowel disease, multiple sclerosis and rheumatoid arthritis (Forbes JD, Chen CY, Knox NC, et al. A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?. Microbiome. 2018; 6(1): 221. Published 2018 Dec 13. doi: 10.1186 / s40168-018-0603-4). In addition, it has been reported that the prevalence of Eggerella bacteria is high in asthma patients (Wang Q, Li F, Liang B, et al. A metagenome-wide association study of gut microbiota in asthma in UK adults. BMC Microbiol. 2018; 18(1): 114. Published 2018 Sep 12. doi: 10.1186 / s12866-018-1257-x).It has been further reported that Eggerella bacteria exacerbate colitis by activating helper T17 cells (Alexander M, Ang QY, Nayak RR, et al. Human gut bacterial metabolism drives Th17 activation and colitis [published online ahead of print, 2021 Nov 18]. Cell Host Microbe. 2021; S1931-3128 (21) 00507-2. doi: 10.1016 / j.chom.2021.11.001) and inactivate digoxin, a cardiotonic drug used to treat heart failure and arrhythmias (Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ. Predicting and manipulating cardiac drug inactivation by the human gut bacteria Eggerthellalenta. Science. 2013; 341(6143): 295-298. doi: 10.1126 / science.1235872). Therefore, the composition can be used to treat any of the group consisting of inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, mood disorders and asthma, or to be administered to patients with colitis that is aggravated by activation of helper T17 cells, or to be administered to patients with heart failure and arrhythmia who take digoxin.
[0186] The Oscillator bacteria involved in the present invention are a type of bacteria that normally live in the human intestine, but in recent years, they have been reported to be associated with various diseases. For example, the occupancy rate of Oscillator bacteria in patients with chronic kidney disease has increased, and it has also been shown to be positively correlated with uremic substances (Kim JE, Kim HE, Park JI, et al. The Association between Gut Microbiota and Uremia of Chronic Kidney Disease. Microorganisms. 2020; 8(6): 907. Published 2020Jun 16. doi: 10.3390 / microorganisms8060907). In addition, it is reported that the occupancy rate of Oscillator bacteria in inflammatory bowel disease model mice is also large (Wang C, Li W, Wang H, et al. Saccharomyces boulardii alleviates ulcerative colitis carcinogenesis in mice by reducing TNF-αand IL-6 levels and functions and by rebalancing intestinal microbiota. BMC Microbiol. 2019; 19 (1): 246. Published 2019 Nov 6. doi: 10.1186 / s12866-019-1610-8). Therefore, the composition can be used to treat any species selected from the group consisting of chronic kidney disease, mood disorders and inflammatory bowel disease.
[0187] It is also reported that the bacteria of the genus Holdermanella involved in the present invention are more abundant in the intestines of patients with Parkinson's disease (Alteration of the fecal microbiota in Chinese patients with Parkinson's disease. Brain Behav Immun. 2018; 70: 194-202. doi: 10.1016 / j.bbi.2018.02.016). Therefore, the composition can be used to treat any species selected from the group consisting of mood disorders and Parkinson's disease.
[0188] The Parasutterella bacteria involved in the present invention are present in the intestines of various animals including humans, mice, dogs, chickens, etc. It is reported that Parasutterella bacteria have a large incidence in patients with irritable bowel syndrome (IBS) (Chen YJ, Wu H, Wu SD, et al. Parasutterella, in association with irritable bowel syndrome and intestinal chronic inflammation. J Gastroenterol Hepatol. 2018; 33 (11): 1844-1852. doi: 10.1111 / jgh.14281), major depressive disorder and depression (the aforementioned non-patent literature 9, 10), and are related to liver dysfunction caused by a high-fat diet (Blasco-Baque V, Coupe B, Fabre A, et al. Associations between hepatic miRNA expression, liver triacylglycerols and gut microbiota during metabolic adaptation to high-fat diet inmice.Diabetologia.2017;60(4):690-700.doi:10.1007 / s00125-017-4209-3). Therefore, the composition can be used to treat any kind selected from the group consisting of mood disorders, irritable bowel syndrome and liver dysfunction.
[0189] Mood disorders are classified as "mental and behavioral disorders" in the 11th revision of the International Classification of Diseases (ICD-11). Mood disorders (sometimes also called affective disorders) (ICD-11, F30-F39) are a general term for states that cause significant interference with daily life due to mood (emotion) fluctuations, including depression, bipolar disorder (manic depression), and dysthymic disorder. Depression refers to a disease state in which mental symptoms such as low mood and unhappiness in doing anything occur throughout the day, as well as physical symptoms such as insomnia, loss of appetite, and fatigue, which cause great interference with daily life. Depressive state (sometimes also called depressive state) refers to a state of persistent depressive mood (a negative emotional state characterized by low mood, sadness, emptiness, despair, or frustration), such as a state in which depressed mood lasts almost all day, almost every day, and lasts for more than two weeks.
[0190] Inflammatory bowel disease includes ulcerative colitis and Crohn's disease. Multiple sclerosis is a disease in which immune cells cause inflammation in the central nervous system (brain / spinal cord) and optic nerves, damaging nerve tissue. It is a type of autoimmune disease. Rheumatoid arthritis is a disease that causes synovial inflammation in the joints. It is a type of autoimmune disease. When kidney function drops below 60% of a healthy person (eGFR is less than 60 ml / min / 1.73 m 2 ) or proteinuria lasts for more than 3 months, it is diagnosed as chronic kidney disease. The causes of chronic kidney disease are varied, for example, diabetes, hypertension, obesity, metabolic syndrome, chronic nephritic syndrome / nephrotic syndrome and other kidney diseases, collagen disease, infectious diseases, genetic abnormalities, medication (antipyretic analgesics, Chinese medicine, anticancer agents, etc.), aging, etc. Inflammatory bowel disease includes ulcerative colitis and Crohn's disease. Parkinson's disease includes Parkinson's disease that occurs in people over 50 years old and juvenile Parkinson's disease.
[0191] In addition, the composition can be used for treating diseases or conditions that can be improved by controlling the growth of bacteria, the bacteria being any species selected from the group consisting of Eggerella, Oscillator, Holdermanella, and Parasutterella in the intestine. Such diseases or conditions may include various mental and behavioral disorders in addition to mood disorders.
[0192] In addition, the composition can be used for treating diseases or conditions that are improved by controlling the proliferation of Eggerthella bacteria in the intestines. Such diseases or conditions include various diseases or conditions in addition to inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, mood disorders, asthma, colitis, heart failure, and arrhythmia.
[0193] In addition, the composition can be used for treating diseases or conditions that can be improved by controlling the proliferation of Oscillator bacteria in the intestines. Such diseases or conditions include various diseases or conditions in addition to chronic kidney disease, mood disorders, and inflammatory bowel disease.
[0194] In addition, the composition can be used for treating diseases or conditions that can be improved by controlling the proliferation of the bacteria of the genus Holdermanella in the intestine. Such diseases or conditions may include various diseases or conditions in addition to mood disorders and Parkinson's disease.
[0195] In addition, the composition can be used for treating diseases or conditions that can be improved by controlling the proliferation of Parasutterella bacteria in the intestines. Such diseases or conditions include various diseases or conditions in addition to mood disorders, irritable bowel syndrome, and liver dysfunction.
[0196] With regard to the present invention, when referring to the treatment of a disease or state, it refers to reducing the risk of disease, delaying disease, preventing, treating, stopping, and delaying progression. Treatment includes radical treatment (treatment to eliminate the cause of disease) and symptomatic treatment (treatment to improve symptoms, such as treatment of symptoms such as loss of appetite, insomnia, fatigue, headache, stiff shoulder joints, palpitations and other physical discomfort during depression). The behavior used to improve or treat includes medical behavior performed by doctors or nurses and midwives who receive instructions from doctors, as well as non-therapeutic behavior performed by personnel other than doctors, such as pharmacists, nutritionists (including management nutritionists, sports nutritionists), health workers, midwives, nurses, clinical examination technicians, sports trainers, drug manufacturers, drug sellers, food manufacturers, food sellers, etc. Furthermore, preventing or reducing the risk of disease includes recommending the intake of specific foods and nutritional guidance (including nutritional guidance required for the recuperation of the wounded and sick, and nutritional guidance for maintaining and promoting health).
[0197] [Composition]
[0198] (Food composition, etc.)
[0199] The composition of the present invention can be made into a food composition or a pharmaceutical composition. Unless otherwise specified, food and medicine include not only food and medicine for human use, but also food and medicine for animals other than humans. Unless otherwise specified, food includes general food, functional food, nutritional composition, and also includes therapeutic food (food for therapeutic purposes. Food cooked based on a diet recipe prescribed by a doctor and a menu prepared by a nutritionist, etc.), dietetic food, formula food, nursing food, and therapeutic auxiliary food. Unless otherwise specified, food includes not only solid food, but also liquid food, such as beverages, health drinks, liquid food and soup. Functional food refers to food that can give a specified functionality to an organism, such as specific health food (including special protection [specific health food] with additional conditions), functional labeled food, health functional food including nutritional functional food, special purpose food, nutritional supplement food, health supplement food, nutritional supplement (such as tablets, coated tablets, sugar-coated tablets, capsules, liquid preparations and other various dosage forms of food), beauty food (such as weight loss food) and other all health foods. In addition, the "functional food" in the present invention includes health foods with health claims based on applicable food standards of the Codex (FAO / WHO Joint Food Standards Commission).
[0200] (Target)
[0201] The composition of the present invention is suitable for administration to the following subjects: the subject desires or needs to control the proliferation of Eggerella bacteria in the intestine; is selected from any of the group consisting of inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, mood disorders and asthma, a patient with colitis aggravated by activation of helper T17 cells, or a patient with heart failure and arrhythmia taking digoxin; and the subject has a disease or condition that is improved by controlling the proliferation of Eggerella bacteria in the intestine. Subjects who desire or need to control the proliferation of Eggerella bacteria in the intestine include those with a large number (or excessive) of Eggerella bacteria in the intestine.
[0202] The composition of the present invention is suitable for administration to the following subjects: the subject desires or needs to control the proliferation of Oscillibacterium bacteria in the intestine; the subject is any one selected from the group consisting of chronic kidney disease, mood disorders and inflammatory bowel disease; and the subject has a disease or condition that is improved by controlling the proliferation of Oscillibacterium bacteria in the intestine. Subjects who desire or need to control the proliferation of Oscillibacterium bacteria in the intestine include those with a large (or excessive) number of Oscillibacterium bacteria in the intestine.
[0203] The composition of the present invention is suitable for administration to the following subjects: the subject desires or needs to control the proliferation of Haldemanella bacteria in the intestine; the subject is any one selected from the group consisting of mood disorders and Parkinson's disease; and the subject has a disease or condition that can be improved by controlling the proliferation of Haldemanella bacteria in the intestine. Subjects who desire or need to control the proliferation of Haldemanella bacteria in the intestine include those with a large (or excessive) number of Haldemanella bacteria in the intestine.
[0204] The composition of the present invention is suitable for administration to the following subjects: the subject desires or needs to control the proliferation of Parasartella bacteria in the intestine; the subject is any one selected from the group consisting of mood disorders, irritable bowel syndrome and liver dysfunction; and the subject has a disease or condition that can be improved by controlling the proliferation of Parasartella bacteria in the intestine. Subjects who desire or need to control the proliferation of Parasartella bacteria in the intestine include those with a large number (or excessive) of Parasartella bacteria in the intestine.
[0205] It should be noted that, in the present invention, the term "administering" refers not only to administering a drug to a subject, but also to causing a subject to ingest food other than a drug.
[0206] The age of the subjects is not particularly limited, and the subjects may be, for example, newborns (within 28 days of birth); infants (under 1 year old); toddlers (1 to 6 years old); children (over 7 years old and under 15 years old); adults (over 15 years old); and people over 65 years old.
[0207] (Given by, etc.)
[0208] The composition of the present invention may be administered orally, parenterally, for example, via a tube (gastrostomy, enterostomy), or nasally, but is preferably administered orally.
[0209] The composition can be administered to the subject repeatedly or continuously for a long period of time. The duration is not particularly limited, but in order to fully observe the effect, it can be administered continuously for a relatively long period of time, such as more than 3 days, more than 1 week, more than 2 weeks, more than 1 month, more than 3 months, more than 6 months, or more than 1 year.
[0210] The composition can be administered daily, in advance when at high risk, or when needed. The composition can be administered as a meal, before, after, or between meals, or when the disease or condition to be improved by the composition occurs.
[0211] (Dosage, content)
[0212] The dosage of the composition of the present invention may be any dosage that can produce the desired effect, and can be appropriately set in consideration of various factors such as the age, weight, and symptoms of the subject.
[0213] The daily dose of the composition can be such that the amount of the active ingredient is 0.1 mg or more, preferably 0.3 mg or more, more preferably 0.6 mg or more, and further preferably 1 mg or more. The upper limit of the active ingredient of the daily dose can be set to 10 g or less, 5 g or less, 1 g or less, 100 mg or less, 60 mg or less, 30 mg or less, or 15 mg or less in any case where the lower limit is any. It should be noted that, in the case where a plurality of active ingredients are included in the composition, the amount of the active ingredient refers to the total amount of the active ingredient contained.
[0214] Administration may be once a day or multiple times a day, for example 2 to 10 times. The dose of the active ingredient each time may be, for example, 0.01 mg or more, preferably 0.03 mg or more, more preferably 0.06 mg or more, and further preferably 0.1 mg or more. The upper limit of the active ingredient each time may be 3 g or less, 1 g or less, 100 mg or less, 33 mg or less, 20 mg or less, 10 mg or less, or 5 mg or less, when the lower limit is any.
[0215] The content of the active ingredient in the composition can be appropriately set according to the form of the composition. For example, relative to the solid content of the composition, the content of the active ingredient can be set to 0.1% or more, preferably 0.3% or more, more preferably 0.6% or more, and further preferably 1% or more. The upper limit value of the active ingredient relative to the solid content can be set to 50% or less, 30% or less, 20% or less, 10% or less, or 5% or less, when the lower limit value is arbitrary. It should be noted that, with respect to the present invention, unless otherwise specified, % refers to mass %.
[0216] When the composition is in liquid form, the content of the active ingredient can be, for example, 0.01% or more, preferably 0.03% or more, more preferably 0.06% or more, and further preferably 0.1% or more. When the composition is in liquid form, the upper limit of the content of the active ingredient can be 5% or less, 3% or less, 2% or less, 1% or less, or 0.5% or less, with the lower limit being any.
[0217] (Other ingredients, additives)
[0218] In the present invention, the composition may contain other effective ingredients and nutritional ingredients that are permitted as food or medicine. Examples of such ingredients are lipids (e.g., milk fat, vegetable oils and fats, oils and fats containing medium-chain fatty acids), proteins (e.g., milk protein, milk protein concentrate (MPC), whey protein concentrate (WPC), whey protein isolate (WPI), α-lactalbumin (α-La), β-lactoglobulin (β-Lg), heat-denatured whey protein, and enzyme-treated whey protein), amino acids (e.g., lysine, arginine, glycine, alanine, glutamic acid, leucine, isoleucine, valine), and oligosaccharides other than human milk. Sugars or sugars other than the constituent sugars of human milk oligosaccharides (glucose, sucrose, fructose, maltose, trehalose, erythritol, maltitol, palatinose, xylitol, dextrin), electrolytes (such as sodium, potassium, calcium, magnesium), vitamins (such as vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, biotin, folic acid, pantothenic acid and niacin), minerals (such as copper, zinc, iron, cobalt, manganese), antibiotics, dietary fiber, etc.
[0219] In the present invention, the composition may contain prebiotics other than human milk oligosaccharides. Prebiotics can be said to be a kind of indigestible food ingredient that has a beneficial effect on the host and improves the health of the host by selectively changing the proliferation and activity of specific bacteria in the large intestine. As prebiotics other than human milk oligosaccharides in the composition, one or more prebiotics can be used.
[0220] Prebiotics other than human milk oligosaccharides are not particularly limited as long as they do not interfere with the effects of the active ingredients contained in the composition. Examples of prebiotics other than human milk oligosaccharides include galacto-oligosaccharides, fructo-oligosaccharides, xylo-oligosaccharides, isomaltooligosaccharides, raffinose, lactulose, lactofructooligosaccharides, soybean oligosaccharides, coffee oligosaccharides, dietary fiber, and gluconic acid.
[0221] In addition, the composition may also contain additives that are permitted as food or medicine. Examples of such additives include inactive carriers (solid, liquid carriers), excipients, surfactants, binders, disintegrants, lubricants, solubilizers, suspending agents, coating agents, colorants, preservatives, buffers, pH regulators, emulsifiers, stabilizers, sweeteners, antioxidants, flavors, acidulants, and natural products. More specifically, water, other aqueous solvents, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymers, sodium alginate, water-soluble dextran, water-soluble dextrin, sodium carboxymethyl starch, pectin, xanthan gum, gum arabic, casein, gelatin, agar, glycerin, propylene glycol, polyethylene glycol, vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin, mannitol, sorbitol, lactose, sucralose, stevioside, aspartame, acesulfame potassium, citric acid, lactic acid, malic acid, tartaric acid, phosphoric acid, acetic acid, fruit juice, vegetable juice, etc.
[0222] (Dosage form / form)
[0223] The food composition of the present invention can be made into any form such as solid, liquid, mixture, suspension, powder, granule, paste, jelly, gel, capsule, etc. In addition, the food composition of the present invention can be made into any form such as dairy products, nutritional supplements, snacks, beverages, health beverages, flavorings, processed foods, side dishes, soups, etc. More specifically, the composition of the present invention can be made into liquid food, semi-liquid food, jelly, gel, powder, formula milk powder, formula liquid milk, milk powder / liquid milk for pregnant women / lactating women, fermented milk, stick, mousse, chocolate, biscuit, ice cream, fermented milk, lactobacillus beverage, milk beverage, milk beverage, refreshing beverage, sheet, cheese, bread, biscuit, cracker, pizza crust, patient food, nutritious food, frozen food, processed food, etc., and can also be made into forms such as granules, powders, pastes, concentrates, etc. for mixing in beverages and foods. Granules and powders can be made into cubes or sticks (small packages for single doses). In relation to the present invention, formula milk powder refers to a powdered product made by processing fresh milk, milk, special milk or fresh buffalo milk or foods made with them as raw materials or as the main raw materials, and adding nutrients required by infants and young children, as defined in Japan's "Ministerial Order on the Standards of Composition of Milk and Dairy Products (hereinafter referred to as "Ministerial Order on Milk, etc."). In relation to the present invention, formula liquid milk refers to a liquid product made by processing fresh milk, milk, special milk or fresh buffalo milk or foods made with them as raw materials or as the main raw materials, and adding nutrients required by infants and young children, as defined in the Provincial Order on Milk, etc.
[0224] Formula milk powder or formula liquid milk (sometimes they are collectively referred to as formula milk powder. In addition, in the description of formula milk powder, formula milk powder is sometimes used as an example, but this description is also applicable to formula liquid milk) can be for infants, older infants (for weaning and complementary food supplementation), low birth weight infants, children, adults, pregnant women, breastfeeding women, the elderly, allergic people, lactose intolerant people, and people with congenital metabolic disorders. Preferred examples of formula milk powder are milk powder for infants, older infants, low birth weight infants, and children.
[0225] The pharmaceutical composition of the present invention can be prepared into solid preparations such as tablets, granules, powders, pills, capsules, etc. suitable for oral administration; liquid preparations such as solutions, suspensions, syrups, etc.; any dosage form such as gels and aerosols.
[0226] (other)
[0227] In the manufacture of the composition of the present invention, the stage of compounding the active ingredient can be appropriately selected. As long as the characteristics of the active ingredient are not significantly damaged, the stage of compounding is not particularly limited. For example, the active ingredient can be mixed with the raw materials and compounded. Alternatively, the composition containing the active ingredient can be manufactured by adding the active ingredient in the final stage of the manufacture.
[0228] The composition of the present invention may be labeled with the intended use (application) and may also be labeled with content that recommends administration to a specific subject.
[0229] The composition of the present invention may indicate the following: the composition or active ingredient can control the proliferation of Eggerella bacteria in the intestine; can inhibit the proliferation of Eggerella bacteria in the intestine; can treat a disease or condition, which is improved by controlling the proliferation of Eggerella bacteria in the intestine (preferably inhibiting proliferation); can be used as a prebiotic; can be used as a synbiotic (a combination of probiotics and prebiotics); or can treat any type selected from the group consisting of inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, mood disorders and asthma; and is suitable for administration to patients with colitis worsened by activation of helper T17 cells, or patients with heart failure and arrhythmias taking digoxin.
[0230] The composition of the present invention may indicate the following: the composition or the active ingredient can control the proliferation of Oscillation Bacterium in the intestine; can inhibit the proliferation of Oscillation Bacterium in the intestine; can treat a disease or condition, which is improved by controlling the proliferation of Oscillation Bacterium in the intestine (preferably inhibiting the proliferation); can be used as a prebiotic; can be used as a synbiotic (composed of a probiotic and a prebiotic); or can treat any type selected from the group consisting of chronic kidney disease, mood disorders and inflammatory bowel disease.
[0231] The composition of the present invention may indicate the following: the composition or the active ingredient can control the proliferation of Holdermanella bacteria in the intestine; can inhibit the proliferation of Holdermanella bacteria in the intestine; can treat a disease or condition, which is improved by controlling the proliferation of Holdermanella bacteria in the intestine (preferably inhibiting proliferation); can be used as a prebiotic; can be used as a synbiotic (composed of a probiotic and a prebiotic); or can treat mood disorders and Parkinson's disease.
[0232] The composition of the present invention may indicate the following: the composition or active ingredient can control the proliferation of Parasartella bacteria in the intestine; can inhibit the proliferation of Parasartella bacteria in the intestine; can treat a disease or condition, which is improved by controlling the proliferation of Parasartella bacteria in the intestine (preferably inhibiting proliferation); can be used as a prebiotic; can be used as a synbiotic (composed of a probiotic and a prebiotic); or can treat mood disorders, irritable bowel syndrome and liver dysfunction.
[0233] Labeling can be direct or indirect. Examples of direct labeling include records on the product itself, packaging, containers, labels, signs and other physical objects. Examples of indirect labeling include advertising / promotional activities conducted through websites, stores, brochures, exhibitions, media seminars and other seminars, books, newspapers, magazines, television, radio, mailings, emails, audio and other places or means.
[0234] The present invention is further described in detail below using examples, but the protection scope of the present invention is not limited to these examples.
[0235] Example
[0236] 1. Embodiments of bacteria belonging to the genus Eggerella:
[0237] [Sugar solution preparation]
[0238] 2'-FL (Jennewein Biotechnologie GmbH.), 3'-SL (Carbosynth), 6'-SL (Tokyo Chemical Industry #S0886), lactose (Fujifilm Wako Pure Chemical Industries, Ltd., #128-00095), and fucose (Fujifilm Wako Pure Chemical Industries, Ltd., #068-05323) were dissolved in sterile water to give 10% by mass, and then sterilized using a 0.22 μm filter (Merck Millipore, #0369).
[0239] [Effects of human milk oligosaccharides on intestinal flora in human fecal culture system]
[0240] The fecal frozen solution provided by 8 healthy adults was thawed in a 37°C water bath. 70 μL of each fecal thaw solution was added to 7 mL of semi-fluid medium (Nissui #05460) for GAM sugar decomposition and cultured at 37°C under anaerobic conditions for 24 hours. 900 μL of each fecal culture solution was dispensed into 6 wells of a 96-well deepwell plate. 100 μL of each sugar solution (5 kinds) or sterilized water was added to the 6 wells (the final concentration of the sugar solution was 1% by mass). After culturing for 48 hours at 37°C under anaerobic conditions, DNA was extracted using Maxwell (company name: Promega) and amplicon sequencing of the V3-V4 region was performed using MiSeq (company name: Illumina). The obtained .fastq file was analyzed using QIIME2 (https: / / qiime2.org / ) to calculate the occupancy of each intestinal bacteria.
[0241] The results are as follows Figure 1 As shown. Compared with the sterile water group as a control, the occupancy rate of Eggerella bacteria in the group added with 2'-FL, 3'-SL, 6'-SL, fucose and lactose was significantly reduced or tended to decrease. Therefore, it is suggested that 2'-FL, 3'-SL, 6'-SL, fucose and lactose inhibit the proliferation of Eggerella bacteria in the human intestine. It should be noted that Bifidobacterium bacteria were detected in all fecal thaw solutions.
[0242] In this example, lactose was confirmed to have an inhibitory effect on the growth of bacteria of the genus Eggerella. HMO contains lactose as a constituent sugar, and it is believed that HMO produces lactose in the human digestive tract after ingestion (Non-Patent Document 13). Therefore, it is believed that as long as it is HMO, the inhibitory effect on the growth of bacteria of the genus Eggerella can be obtained.
[0243] In this example, the growth inhibitory effect of fucose on bacteria of the genus Eggerella was confirmed. It is believed that HMO containing fucose as a constituent sugar produces fucose in the human digestive tract after ingestion (Non-patent Documents 13, 14). Therefore, it is believed that as long as it is an HMO containing fucose as a constituent sugar (fucosylated HMO, fucose-containing HMO), the growth inhibitory effect of bacteria of the genus Eggerella can be obtained.
[0244] In this example, 2'-FL, 3'-SL, and 6'-SL were all confirmed to have growth inhibitory effects on bacteria of the genus Eggerella, so it is considered that growth inhibitory effects on bacteria of the genus Eggerella can be obtained as long as they are fucosylated HMO and sialylated HMO.
[0245] 2. Embodiments of bacteria of the genus Oscillator:
[0246] <Example 1>
[0247] [Sugar solution preparation]
[0248] 2′-FL (Jennewein Biotechnologie GmbH.) and lactose (Fujifilm Wako Pure Chemical Industries, Ltd., #128-00095) were dissolved in sterile water to give 10% by mass, and then sterilized using a 0.22 μm filter (Merck Millipore, #0369).
[0249] [Effects of human milk oligosaccharides on intestinal flora in human fecal culture system]
[0250] The fecal frozen solution provided by 8 healthy adults was thawed in a 37°C water bath. 60 μL of each fecal thaw solution was added to 6 mL of semi-fluid medium (Nissui #05460) for GAM sugar decomposition and cultured at 37°C under anaerobic conditions for 24 hours. 900 μL of each fecal culture solution was dispensed into 5 wells of a 96-well deep-well plate. 100 μL of each sugar solution (4 kinds) or sterilized water was added to the 5 wells (the final concentration of the sugar solution was 1% by mass). After culturing for 24 hours at 37°C under anaerobic conditions, DNA was extracted using Maxwell (company name: Promega) and amplicon sequencing of the V3-V4 region was performed using MiSeq (company name: Illumina). The obtained .fastq file was analyzed using QIIME2 (https: / / qiime2.org / ) to calculate the occupancy of each intestinal bacteria.
[0251] The results are as follows Figure 2 As shown. Compared with the control sterile water group, the occupancy rate of Oscillator bacteria in the group added with 2'-FL and lactose was significantly reduced. Therefore, it is suggested that 2'-FL and lactose inhibit the proliferation of Oscillator bacteria in the human intestine. It should be noted that Bifidobacterium bacteria were detected in all fecal thaw solutions.
[0252] <Example 2>
[0253] [Sugar solution preparation]
[0254] Fucose (Fujifilm Wako Pure Chemical Industries, Ltd. #068-05323) was dissolved in sterile water to give 10% by mass, and then sterilized using a 0.22 μm filter (Merck Millipore #0369).
[0255] [Effects of human milk oligosaccharides on intestinal flora in human fecal culture system]
[0256] The fecal frozen solution provided by 8 healthy adults was thawed in a 37°C water bath. 30 μL of each fecal thaw solution was added to 3 mL of semi-fluid medium (Nissui #05460) for GAM sugar decomposition and cultured at 37°C under anaerobic conditions for 24 hours. 900 μL of each fecal culture solution was dispensed into 2 wells of a 96-well deep-well plate. 100 μL of sugar solution or sterilized water was added to each well (the final concentration of the sugar solution was 1% by mass). After culturing for 48 hours at 37°C under anaerobic conditions, DNA was extracted using Maxwell (company name: Promega) and amplicon sequencing of the V3-V4 region was performed using MiSeq (company name: Illumina). The obtained .fastq file was analyzed using QIIME2 (https: / / qiime2.org / ) to calculate the occupancy of each intestinal bacteria.
[0257] The results are as follows Figure 3 As shown. Compared with the sterile water group as a control, the occupancy rate of Oscillator bacteria in the group supplemented with fucose tended to decrease. Therefore, it is suggested that fucose inhibits the proliferation of Oscillator bacteria in the human intestine. It should be noted that Bifidobacterium bacteria were detected in all fecal thaw solutions.
[0258] Summary
[0259] In this example, lactose was confirmed to have an inhibitory effect on the growth of Oscillator bacteria. HMO contains lactose as a constituent sugar, and it is believed that HMO produces lactose in the human digestive tract after ingestion (Non-Patent Document 13). Therefore, it is believed that any HMO can obtain an inhibitory effect on the growth of Oscillator bacteria.
[0260] In this example, the growth inhibitory effect of fucose on bacteria of the genus Oscillator was confirmed. It is believed that HMO containing fucose as a constituent sugar produces fucose in the human digestive tract after ingestion (Non-patent Documents 13 and 14). Therefore, it is believed that as long as it is an HMO containing fucose as a constituent sugar (fucosylated HMO, fucose-containing HMO), the growth inhibitory effect on bacteria of the genus Oscillator can be obtained.
[0261] In this example, the growth inhibitory effect of 2'-FL on bacteria of the genus Oscillibacter was confirmed. Therefore, it is considered that any fucosylated HMO can obtain the growth inhibitory effect on bacteria of the genus Oscillibacter.
[0262] 3. Embodiments concerning bacteria of the genus Holdemanella:
[0263] [Sugar solution preparation]
[0264] 2'-FL (Jennewein Biotechnologie GmbH), 3'-SL (Carbosynth), 6'-SL (Tokyo Chemical Industry, #S0886), lactose (Fujifilm Wako Pure Chemical Industries, Ltd., #128-00095) and Neu5Ac (Fujifilm Wako Pure Chemical Industries, Ltd., #011-26173) were dissolved in sterile water to give 10% by mass, and then sterilized using a 0.22 μm filter (Merck Millipore, #0369).
[0265] [Effects of human milk oligosaccharides on intestinal flora in human fecal culture system]
[0266] The fecal frozen solution provided by 8 healthy adults was thawed in a 37°C water bath. 70 μL of each fecal thaw solution was added to 7 mL of a semi-fluid medium (Nissui, #05460) for GAM sugar decomposition and cultured at 37°C and anaerobic conditions for 24 hours. 900 μL of each fecal culture solution was dispensed into 6 wells of a 96-well deep-well plate. 100 μL of each sugar solution (5 kinds) or sterilized water was added to the 6 wells (the final concentration of the sugar solution was 1% by mass). After culturing for 48 hours at 37°C and anaerobic conditions, DNA was extracted using Maxwell (company name: Promega) and amplicon sequencing of the V3-V4 region using MiSeq (company name: Illumina) was performed.
[0267] The results are as follows Figure 4 As shown. Compared with the control sterile water group, the occupancy rate of Holdermanella bacteria in the group supplemented with 2'-FL, 3'-SL, 6'-SL, lactose, and Neu5Ac was significantly reduced. Therefore, it is suggested that 2'-FL, 3'-SL, 6'-SL, lactose, and Neu5Ac inhibit the proliferation of Holdermanella bacteria in the human intestine. It should be noted that Bifidobacterium bacteria were detected in all fecal thaw solutions.
[0268] In this example, lactose was confirmed to have an inhibitory effect on the growth of bacteria of the genus Holdermanella. HMO contains lactose as a constituent sugar, and it is believed that HMO produces lactose in the human digestive tract after ingestion (Non-Patent Document 12). Therefore, it is believed that any HMO can obtain an inhibitory effect on the growth of bacteria of the genus Holdermanella.
[0269] In this example, the growth inhibitory effect of Neu5Ac on bacteria of the genus Holdermanella was confirmed. It is believed that HMO containing Neu5Ac as a constituent sugar produces Neu5Ac in the human digestive tract after ingestion (Non-patent Documents 13, 15, 16). Therefore, it is believed that as long as the HMO (sialylated HMO, sialic acid-containing HMO) contains Neu5Ac as a constituent sugar, the growth inhibitory effect on bacteria of the genus Holdermanella can be obtained.
[0270] In this example, 2'-FL, 3'-SL, and 6'-SL were all confirmed to have growth inhibitory effects on bacteria of the genus Haldemannia. Therefore, it is believed that growth inhibitory effects on bacteria of the genus Haldemannia can be obtained as long as they are fucosylated HMO and sialylated HMO.
[0271] 4. Embodiments concerning Parasartella bacteria:
[0272] <Example 1>
[0273] [Sugar solution preparation]
[0274] 2'-FL (Jennewein Biotechnologie GmbH.), 3'-SL (Carbosynth), lactose (Fujifilm Wako Pure Chemical Industries, Ltd., #128-00095) and Neu5Ac (Fujifilm Wako Pure Chemical Industries, Ltd., #011-26173) were dissolved in sterile water to give 10% by mass, and then sterilized using a 0.22 μm filter (Merck Millipore, #0369).
[0275] [Effects of human milk oligosaccharides on intestinal flora in human fecal culture system]
[0276] The fecal frozen solution provided by 8 healthy adults was thawed in a 37°C water bath. 60 μL of each fecal thaw solution was added to 6 mL of semi-fluid medium (Nissui #05460) for GAM sugar decomposition and cultured at 37°C under anaerobic conditions for 24 hours. 900 μL of each fecal culture solution was dispensed into 5 wells of a 96-well deep-well plate. 100 μL of each sugar solution (4 kinds) or sterilized water was added to the 5 wells (the final concentration of the sugar solution was 1% by mass). After culturing for 24 hours at 37°C under anaerobic conditions, DNA was extracted using Maxwell (company name: Promega) and amplicon sequencing of the V3-V4 region was performed using MiSeq (company name: Illumina). The obtained .fastq file was analyzed using QIIME2 (https: / / qiime2.org / ) to calculate the occupancy of each intestinal bacteria.
[0277] The results are as follows Figure 5 As shown. Compared with the control sterile water group, the occupancy rate of Parasutterella bacteria in the group added with 2'-FL, 3'-SL, lactose and Neu5Ac was significantly reduced. Therefore, it is suggested that 2'-FL, 3'-SL, lactose and Neu5Ac inhibit the proliferation of Parasutterella bacteria in the human intestine. It should be noted that Bifidobacterium bacteria were detected in all fecal thaw solutions.
[0278] <Example 2>
[0279] [Sugar solution preparation]
[0280] 6'-SL (Tokyo Chemical Industry #S0886) was dissolved in sterile water to give 10% by mass, and then sterilized using a 0.22 μm filter (Merck Millipore #0369).
[0281] [Effects of human milk oligosaccharides on intestinal flora in human fecal culture system]
[0282] The fecal frozen solution provided by 8 healthy adults was thawed in a 37°C water bath. 30 μL of each fecal thaw solution was added to 3 mL of semi-fluid medium (Nissui #05460) for GAM sugar decomposition and cultured at 37°C under anaerobic conditions for 24 hours. 900 μL of each fecal culture solution was dispensed into 2 wells of a 96-well deep-well plate. 100 μL of sugar solution or sterilized water was added to each well (the final concentration of the sugar solution was 1% by mass). After culturing for 24 hours at 37°C under anaerobic conditions, DNA was extracted using Maxwell (company name: Promega) and amplicon sequencing of the V3-V4 region was performed using MiSeq (company name: Illumina). The obtained .fastq file was analyzed using QIIME2 (https: / / qiime2.org / ) to calculate the occupancy of each intestinal bacteria.
[0283] The results are as follows Figure 6 Compared with the distilled water group as a control, the occupancy rate of Parasutterella bacteria in the group supplemented with 6'-SL tended to decrease.
[0284] Therefore, it is suggested that 6'-SL inhibits the proliferation of Parasutterella bacteria in the human intestine. It should be noted that Bifidobacterium bacteria were detected in all fecal lysates.
[0285] Summary
[0286] In this example, lactose was confirmed to have an inhibitory effect on the growth of Parasutterella bacteria. HMO contains lactose as a constituent sugar, and it is believed that HMO produces lactose in the human digestive tract after ingestion (Non-Patent Document 13). Therefore, it is believed that as long as it is HMO, the growth inhibitory effect of Parasutterella bacteria can be obtained.
[0287] In this example, the growth inhibition effect of Neu5Ac on Parasartella bacteria was confirmed. It is believed that HMO containing Neu5Ac as a constituent sugar produces Neu5Ac in the human digestive tract after ingestion (Non-patent Documents 13, 15, 16). Therefore, it is believed that as long as the HMO (sialylated HMO, sialic acid-containing HMO) contains Neu5Ac as a constituent sugar, the growth inhibition effect of Parasartella bacteria can be obtained.
[0288] In this example, 2'-FL, 3'-SL, and 6'-SL were all confirmed to have growth inhibitory effects on Parasutterella bacteria, so it is believed that growth inhibitory effects on Parasutterella bacteria can be obtained as long as they are fucosylated HMOs and sialylated HMOs.
[0289] 5. Papers cited in the examples
[0290] Non-patent literature 13: Masi AC, Stewart CJ. Untangling human milkoligosaccharides and infant gut microbiome. iScience. 2021; 25(1): 103542. Published 2021Dec 1. doi: 10.1016 / j.isci.2021.103542
[0291] Non - Patent Document 14: Katayama T, Sakuma A, Kimura T, Makimura Y, Hiratake J, Sakata K, Yamanoi T, Kumagai H, Yamamoto K. Molecular cloning and characterization of Bifidobacterium bifidum 1,2 - alpha - L - fucosidase (AfcA), a novel inverting glycosidase (glycoside hydrolase family 95). J Bacteriol. 2004 Aug;186(15):4885 - 93. doi:10.1128 / JB.186.15.4885 - 4893.2004. PMID:15262925; PMCID:PMC451662.
[0292] Non - Patent Document 15: Nishiyama K, Yamamoto Y, Sugiyama M, et al. Bifidobacterium bifidum Extracellular Sialidase Enhances Adhesion to the Mucosal Surface and Supports Carbohydrate Assimilation. mBio. 2017;8(5):e00928 - 17. Published 2017 Oct 3. doi:10.1128 / mBio.00928 - 17
[0293] Non - Patent Document 16: Kiyohara M, Tanigawa K, Chaiwangsri T, Katayama T, Ashida H, Yamamoto K. An exo - alpha - sialidase from bifidobacteria involved in the degradation of sialyloligosaccharides in human milk and intestinal glycoconjugates. Glycobiology. 2011;21(4):437 - 447. doi:10.1093 / glycob / cwq175。
Claims
1. A composition for controlling bacterial proliferation, comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides, wherein the bacteria are any species selected from the group consisting of Eggerthella bacteria, Oscillibacter bacteria, Holdemania bacteria and Parasutterella bacteria in intestinal flora.
2. The composition according to claim 1, which is used for controlling the proliferation of bacteria of the genus Eggerella, the composition comprising any one selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides containing lactose as a constituent sugar, human milk oligosaccharides containing fucose as a constituent sugar, lactose and fucose. 3 . The composition according to claim 2 , comprising any one selected from the group consisting of 2′-fucosyllactose, 3′-sialyllactose, 6′-sialyllactose, lactose and fucose.
4. The composition according to claim 1, which is used for controlling the proliferation of any bacteria selected from the group consisting of Eggerella bacteria and Oscillocobacter bacteria, the composition comprising any one selected from the group consisting of fucosylated human milk oligosaccharides, human milk oligosaccharides containing lactose as a constituent sugar, human milk oligosaccharides containing fucose as a constituent sugar, lactose and fucose. The composition according to claim 4 , comprising any one selected from the group consisting of 2′-fucosyllactose, lactose and fucose.
6. The composition according to claim 1, which is used for controlling the proliferation of any bacteria selected from the group consisting of bacteria of the genus Holdermanella and bacteria of the genus Parasutterella, the composition comprising any one selected from the group consisting of fucosylated human milk oligosaccharides, sialylated human milk oligosaccharides, human milk oligosaccharides containing lactose as a constituent sugar, human milk oligosaccharides containing sialic acid as a constituent sugar, lactose and sialic acid. 7 . The composition according to claim 6 , comprising any one selected from the group consisting of 2′-fucosyllactose, 3′-sialyllactose, 6′-sialyllactose, lactose, and N-acetylneuraminic acid.
8. The composition according to any one of claims 1 to 7, for use as a prebiotic or synbiotic.
9. The composition according to any one of claims 1 to 7, for use in the treatment of mood disorders.
10. A composition for treating a disease or condition improved by controlling the proliferation of bacteria, comprising any species selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides, wherein the bacteria is any species selected from the group consisting of Eggertella, Oscillator, Holdermanella, and Parasutterella bacteria in the intestine.
11. A composition for treating mood disorders, comprising any one selected from the group consisting of human milk oligosaccharides and constituent sugars of human milk oligosaccharides.
12. The composition according to any one of claims 1 to 7, wherein Proliferation control is proliferation inhibition.
